The Evolving Treatment Landscape in Light Chain Amyloidosis with Cardiac Involvement - Episode 8

Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

January 15, 2024

Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: AL Amyloidosis: Background, Patient Profile, and Staging

EP. 2: Navigating the Differential Diagnosis of AL Amyloidosis

EP. 3: Treatment Approaches in AL Amyloidosis

EP. 4: Limitations of Available Treatment Options for Patients with Cardiac Involvement

EP. 5: Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

EP. 6: Birtamimab Safety Profile in the VITAL Study

EP. 7: Adverse Event Management in AL Amyloidosis

Now Viewing

EP. 8: Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

EP. 9: Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

EP. 10: Clinical Pearls and Future Directions in AL Amyloidosis